Compare Nuwellis Inc (NUWE) vs Prudential PLC (PUK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuwellis Inc vs Prudential PLC — how do they compare? Nuwellis Inc trades at $0.68 (market cap $2.20M), while Prudential PLC trades at $24.03 (market cap $28.76B). The key difference: Prudential PLC is far larger — about 13072.7× Nuwellis Inc's market cap, and Prudential PLC pays a 2.36% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nuwellis Inc for 26 Days and Prudential PLC for 119 Days on average.
| NUWE | PUK | |
|---|---|---|
Market Cap | $2.20M | $28.76B |
Volume | 121,544 | 1,285,651 |
Sector | Health | Financials |
52-Week High | $146.65 | $33.61 |
52-Week Low | $0.68 | $23.54 |
Typical Hold Time | 26 Days | 119 Days |
Enterprise Value | -$1.52M | $28.30B |
Dividend Yield | — | 2.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
PUK trades at $23.88, down 2.93% over 24 hours, amid a bearish technical signal. The company reported strong revenue growth to $27.39B in 2025 and net income of $3.98B, with a net margin of 14.52%. Recent earnings show mixed quarterly results, with two beats and two misses versus expectations. Analyst consensus is moderately bullish, with 50% buy ratings. The firm is executing a strategic overhaul, including a $3B capital rotation plan and exiting certain markets to sharpen focus.
The outlook is cautiously optimistic given solid profitability and strategic initiatives, but near-term headwinds include earnings volatility and bearish technical indicators. Risks involve execution of the restructuring and macroeconomic pressures. The stock presents a value opportunity with a low P/E of 8.28, though investors should weigh the mixed earnings record against growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →About Prudential PLC
Prudential is an Asia and Africa health and life insurance business and is focused on long-term savings. The business is increasingly focusing on digital offerings and creating strong brand equity and relationships with customers of its products through these.
Read more on PUK →
